Literature DB >> 6265138

Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response.

F Boomsma, J H de Bruyn, F H Derkx, M A Schalekamp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6265138     DOI： 10.1042/cs0600491

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN： 0143-5221            Impact factor:   6.124


× No keyword cloud information.
  15 in total

1.  Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus.

Authors:  F Boomsma; U Pedersen-Bjergaard; B Agerholm-Larsen; H Hut; S S Dhamrait; B Thorsteinsson; A H van den Meiracker
Journal:  Diabetologia       Date:  2005-04-14       Impact factor: 10.122

2.  Prolonged converting enzyme inhibition following captopril in patients with renal insuffficiency.

Authors:  B C Campbell; A N Shepherd; H L Elliott; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

3.  Concentration effect modelling with converting enzyme inhibitors in man.

Authors:  A W Kelman; J L Reid; J A Millar
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

Review 4.  Clinical consequences of abrupt drug withdrawal.

Authors:  C F George; D Robertson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

5.  Increased angiotensin-converting enzyme in peripheral blood monocytes from patients with sarcoidosis.

Authors:  T Okabe; K Yamagata; M Fujisawa; J Watanabe; F Takaku; J J Lanzillo; B L Fanburg
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

Review 6.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

7.  Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure.

Authors:  A B Atkinson; A M Cumming; J J Brown; R Fraser; B Leckie; A F Lever; J J Morton; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Captopril plus hydrochlorothiazide once daily normalizes 24 h blood pressure in patients with essential hypertension.

Authors:  J L Meijer; H G Ardesch; J C Van Rooijen; J H De Bruijn
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

9.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

Authors:  J A Millar; F H Derkx; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

10.  Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.

Authors:  F Boomsma; J D Meerwaldt; A J Man in't Veld; A Hovestadt; M A Schalekamp
Journal:  J Neurol       Date:  1989-05       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.